Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Change in Acquisitions & Divestments came in at $159.0 million in Q2 2026, down 78.37% year-over-year from $735.0 million in Q2 2025, and down 23.92% quarter-over-quarter from $209.0 million in Q1 2026.
Analysis
Johnson & Johnson (JNJ) Change in Acquisitions & Divestments (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $159.0 million for Q2 2026.
- In Q2 2026, Change in Acquisitions & Divestments fell 78.37% year-over-year to $159.0 million; the TTM figure through Jun 2026 stood at $1.1 billion (down 37.04% YoY), while the FY2025 annual figure was $1.7 billion, down 32.53% from the prior year.
- Change in Acquisitions & Divestments came in at $159.0 million for Q2 2026 at Johnson & Johnson, down from $209.0 million in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $24.8 billion in Q1 2023 to a low of $159.0 million in Q2 2026.
- Average Change in Acquisitions & Divestments over 5 years is $3.4 billion, with a median of $731.0 million recorded in 2024.
- Year-over-year, Change in Acquisitions & Divestments grew 23.21% in 2023 and slumped 91.95% in 2024.
- Over 5 years, Change in Acquisitions & Divestments stood at $6.3 billion in 2022, then tumbled by 42.84% to $3.6 billion in 2023, then tumbled by 91.95% to $290.0 million in 2024, then dropped by 24.48% to $219.0 million in 2025, then dropped by 27.4% to $159.0 million in 2026.
- Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $159.0 million in Q2 2026, $209.0 million in Q1 2026, and $219.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 159.00 Mn |
| Mar 29, 2026 | 209.00 Mn |
| Dec 28, 2025 | 219.00 Mn |
| Sep 28, 2025 | 489.00 Mn |
| Jun 29, 2025 | 735.00 Mn |
| Mar 30, 2025 | 218.00 Mn |
| Dec 29, 2024 | 290.00 Mn |
| Sep 29, 2024 | 466.00 Mn |
| Jun 30, 2024 | 727.00 Mn |
| Mar 31, 2024 | 979.00 Mn |
| Dec 31, 2023 | 3.60 Bn |
| Oct 1, 2023 | 3.91 Bn |
| Jul 2, 2023 | 4.11 Bn |
| Apr 2, 2023 | 7.77 Bn |
| Jan 1, 2023 | 24.80 Bn |
| Apr 3, 2022 | 6.30 Bn |
| Oct 3, 2021 | 4.36 Bn |
| Jul 4, 2021 | 7.22 Bn |
| Apr 4, 2021 | 5.23 Bn |
| Jan 3, 2021 | 5.55 Bn |